FDA greenlights Medtronic’s dual-energy ablation—could this be the future of AFib treatment?
Medtronic has achieved a major milestone with the U.S. Food and Drug Administration (FDA) granting approval for its Affera Mapping and Ablation System, including the ... Read More
Indoco Remedies secures final USFDA approval for generic Cetirizine Hydrochloride tablets
Indoco Remedies Limited has secured a significant regulatory win by receiving final approval from the United States Food and Drug Administration (USFDA) for its generic ... Read More
Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with ... Read More
Johnson & Johnson faces additional $1.1bn payout in talc lawsuit settlement
Johnson & Johnson is set to pay an additional $1.1 billion to settle tens of thousands of lawsuits claiming its baby powder and other talc-based ... Read More
Johnson & Johnson to acquire V-Wave Ltd. in $1.1bn deal to enhance heart failure treatment
Johnson & Johnson (NYSE: JNJ) has made headlines with its decision to acquire V-Wave Ltd., a private company renowned for its cutting-edge treatments for heart ... Read More
FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced ... Read More
Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant ... Read More
How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment
Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of Numab Therapeutics, for a substantial $1.25 billion. ... Read More
Johnson & Johnson’s TB drug SIRTURO receives full approval from FDA and EC
In a significant development for the treatment of drug-resistant tuberculosis (TB), Johnson & Johnson has announced that SIRTURO (bedaquiline) has received full approval from the ... Read More
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More